Selank vs N-Acetyl Selank Amidate
The Selank-analogue comparison mirrors the Semax parent-analogue question. N-Acetyl Selank Amidate is chemically the same tuftsin-derived heptapeptide as Selank, protected at both termini to resist the aminopeptidase and carboxypeptidase enzymes that clear the parent from plasma. The pharmacology is identical — enkephalinase-inhibition anxiolysis without GABA-A binding — but the practical pharmacokinetics differ substantially.
At a glance
| Selank | N-Acetyl Selank | |
|---|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ |
| Molecular weight | 751.87 g/mol | ~807 g/mol (with terminal modifications) |
| Plasma half-life | Minutes (parent peptide) | Several-fold longer (approximately 3–5× parent) |
| Anxiolytic mechanism | Enkephalinase inhibition, no GABA-A binding | Same mechanism, extended exposure |
| Typical dosing frequency | 2–3× daily in published Russian protocols | 1–2× daily in research protocols |
| Clinical approval | Approved in Russia for anxiolytic indication | No clinical approval; research chemical only |
| Evidence base | Deep — Russian clinical trials versus benzodiazepines | Sparser — analogue-specific data is thinner |
| Route | Intranasal (primary) | Intranasal (primary) |
| Evidence tier | A | C (limited human data specific to analogue) |
| UK status | Research chemical | Research chemical |
Selection guidance
Which analogue for which research design
Parent Selank
N-Acetyl Selank
Chemistry of the modification
What the acetyl and amide termini actually do
The N-terminal acetylation and C-terminal amidation are precise structural modifications designed to solve a specific pharmacokinetic problem. Native Selank has free amino and carboxyl groups at its termini — the natural entry points for aminopeptidase and carboxypeptidase enzymes that cleave peptides from the ends inward. In the plasma and at brain-parenchymal interfaces these terminal peptidases produce most of the parent Selank's clearance.
Blocking the N-terminus with an acetyl group and the C-terminus with an amide converts both termini to structures that aminopeptidases and carboxypeptidases cannot efficiently engage. Endogenous internal-peptidase pathways still process the modified compound, but the rate-limiting step is now slower, extending plasma half-life several-fold and flattening the exposure profile across the dosing interval.
The internal sequence — the tuftsin-derived heptapeptide that carries the actual enkephalinase-inhibition pharmacology — is unchanged. Downstream mechanism-of-action framing is essentially identical between parent and analogue; only the exposure profile differs.
Practical research selection
Selank versus N-Acetyl Selank in specific research contexts
For acute-effect research designs — single-dose administration protocols probing immediate anxiolytic or attention effects — parent Selank's shorter half-life is not a research-design constraint. The established Russian clinical trial protocols use parent Selank, and the deep evidence base makes parent Selank the reference-standard choice for acute-research contexts.
For chronic-effect research designs — extended dosing intervals, sustained-anxiety research models, chronic-effect endpoint measures — N-Acetyl Selank's extended pharmacokinetic profile provides research-design advantages. Less-frequent dosing produces more stable plasma exposure and reduces the fraction of the inter-dose interval spent at subtherapeutic exposure.
For research designs that need directly comparable results to the published Russian clinical evidence base, parent Selank is the reference-standard tool. For research designs that need the extended-exposure advantage, N-Acetyl Selank is the more practical tool. Both compounds are research chemicals in UK and Western contexts and are not licensed medicinal products.